Related Experiment Video

Updated: May 4, 2026

"Sun's Seven-Step Technique" for Endoscopic En-Bloc Resection of Thyroid Cancer via the Chest-Breast Approach
07:45

"Sun's Seven-Step Technique" for Endoscopic En-Bloc Resection of Thyroid Cancer via the Chest-Breast Approach

Published on: November 28, 2025

284

Laryngeal neuroma in multiple endocrine neoplasia type 2B

Naomi Kudo1, Atsushi Matsubara1, Takahisa Abe1

  • 1Department of Otorhinolaryngology, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki 036-8562, Japan.

Auris, Nasus, Larynx
|January 7, 2014
PubMed

Insights

Multiple endocrine neoplasia type 2B (MEN2B) is a rare genetic disorder. This report details an unusual case of laryngeal neuromas associated with MEN2B, highlighting a less common clinical manifestation.

Area of Science:

  • Endocrinology
  • Genetics
  • Oncology

Background:

  • Multiple endocrine neoplasia type 2 (MEN2) is an autosomal dominant inherited disorder.
  • It is caused by mutations in the RET proto-oncogene.
  • MEN2 presents in three main phenotypes: MEN2A, MEN2B, and familial medullary thyroid carcinoma.

Observation:

  • Multiple mucosal neuromas are a common feature in MEN2B.
  • Laryngeal neuroma is an infrequent finding in MEN2B patients.
  • This study reports a rare case of laryngeal mucosal neuromas in a patient with MEN2B.

Findings:

  • The case highlights laryngeal neuroma as a potential, albeit rare, manifestation of MEN2B.
  • This expands the known clinical spectrum of MEN2B-associated mucosal neuromas.

Implications:

  • Increased awareness of laryngeal neuroma in MEN2B may improve early diagnosis.
  • This case underscores the importance of thorough clinical evaluation for diverse presentations of genetic syndromes.
  • Further research into the specific mechanisms causing laryngeal involvement in MEN2B may be warranted.
Keywords:
Laryngeal neuromaMucosal neuromaMultiple endocrine neoplasia

More Related Videos

Author Spotlight: Advancing Awake Nasotracheal Intubation with Flexible Video Rhino-Laryngoscopes03:58

Author Spotlight: Advancing Awake Nasotracheal Intubation with Flexible Video Rhino-Laryngoscopes

Published on: August 2, 2024

2.9K
Transoral Endoscopic Thyroidectomy Vestibular Approach for Thyroid Lobectomy05:12

Transoral Endoscopic Thyroidectomy Vestibular Approach for Thyroid Lobectomy

Published on: May 12, 2023

5.8K

Related Concept Videos

Cushing Syndrome II: Pathophysiology01:19

Cushing Syndrome II: Pathophysiology

Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features...
24
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH...
28
Esophageal Achalasia01:27

Esophageal Achalasia

Esophageal achalasia is a chronic neurogenic disorder characterized by impaired relaxation of the lower esophageal sphincter (LES) and absent or ineffective peristalsis in the distal esophagus. This leads to a functional obstruction without a physical blockage, despite significant disruption of esophageal motility.EtiologyAchalasia is caused by degeneration of the myenteric (Auerbach's) plexus, specifically the loss of inhibitory ganglion cells that produce vasoactive intestinal peptide...
45